Diese Publikation wird Ihnen präsentiert durch Paradigm Publishing Services
University of Chicago Press
Kapitel
Lizenziert
Nicht lizenziert
Erfordert eine Authentifizierung
Subject Index
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Sie haben derzeit keinen Zugang zu diesem Inhalt.
Kapitel in diesem Buch
- Frontmatter i
- Contents vii
- Acknowledgment ix
- Introduction 1
- 1. The Economic Value and Pricing of Personalized Medicine 9
- 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS 21
- 3. The Value of Pharmacogenomic Information 53
- 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory 87
- 5. Characterizing the Drug Development Pipeline for Precision Medicines 115
- 6. Cost Sharing in Insurance Coverage for Precision Medicine 159
- 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments 185
- 8. Physicians’ Financial Incentives to Personalize Medicine 217
- 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan 237
- 10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger 273
- 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 305
- Contributors 335
- Author Index 339
- Subject Index 345
Kapitel in diesem Buch
- Frontmatter i
- Contents vii
- Acknowledgment ix
- Introduction 1
- 1. The Economic Value and Pricing of Personalized Medicine 9
- 2. Therapeutic Translation of Genomic Science: Opportunities and Limitations of GWAS 21
- 3. The Value of Pharmacogenomic Information 53
- 4. The Information Pharms Race and Competitive Dynamics of Precision Medicine: Insights from Game Theory 87
- 5. Characterizing the Drug Development Pipeline for Precision Medicines 115
- 6. Cost Sharing in Insurance Coverage for Precision Medicine 159
- 7. Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments 185
- 8. Physicians’ Financial Incentives to Personalize Medicine 217
- 9. Economic Dimensions of Personalized and Precision Medicine in Asia: Evidence from Breast Cancer Treatment in Taiwan 237
- 10. The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger 273
- 11. Orphan Drug Designations as Valuable Intangible Assets for IPO Investors in Pharma-Biotech Companies 305
- Contributors 335
- Author Index 339
- Subject Index 345
